Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuta Tomida

Showing results (141-150 of 169) with videos related to

Pageof 17
Sort By:
Journal of Molecular Medicine (Berlin, Germany)|December 17, 2023
Correction to: Periostin secreted by cancer‑associated fibroblasts promotes cancer progression and drug resistance in non‑small cell lung cancerFumiaki Takatsu, Ken Suzawa, Shuta Tomida, et al.
Scientific Reports|December 24, 2016
Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathwayTomoaki Ohtsuka, Masakiyo Sakaguchi, Hiromasa Yamamoto, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 13, 2023
Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancerFumiaki Takatsu, Ken Suzawa, Shuta Tomida, et al.
Cancer Immunology Research|July 1, 2025
Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor ImmunityYuto Naoi, Yumi Inukai, Tomoka Izumikawa, et al.
Oncology Research|September 20, 2017
β-1,3-Galactosyl-<i>O</i>-Glycosyl-Glycoprotein β-1,6-<i>N</i>-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer MotilityI Wayan Sumardika, Chen Youyi, Eisaku Kondo, et al.
JAMA Oncology|October 15, 2020
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical TrialHidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami, et al.
Plos One|February 4, 2017
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancerTatsuaki Takeda, Hiromasa Yamamoto, Hirotaka Kanzaki, et al.
Journal of Molecular Medicine (Berlin, Germany)|November 10, 2020
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosisKota Araki, Rie Kinoshita, Nahoko Tomonobu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 3, 2019
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation BurdenGo Makimoto, Kadoaki Ohashi, Shuta Tomida, et al.
Journal of Gastroenterology|November 14, 2023
Marked intestinal trans-differentiation by autoimmune gastritis along with ectopic pancreatic and pulmonary trans-differentiationChihiro Takeuchi, Junichi Sato, Nobutake Yamamichi, et al.
Pageof 17

Showing results (141-150 of 169) with videos related to

Sort By:
Pageof 17
Journal of Molecular Medicine (Berlin, Germany)|December 17, 2023
Correction to: Periostin secreted by cancer‑associated fibroblasts promotes cancer progression and drug resistance in non‑small cell lung cancerFumiaki Takatsu, Ken Suzawa, Shuta Tomida, et al.
Scientific Reports|December 24, 2016
Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathwayTomoaki Ohtsuka, Masakiyo Sakaguchi, Hiromasa Yamamoto, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 13, 2023
Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancerFumiaki Takatsu, Ken Suzawa, Shuta Tomida, et al.
Cancer Immunology Research|July 1, 2025
Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor ImmunityYuto Naoi, Yumi Inukai, Tomoka Izumikawa, et al.
Oncology Research|September 20, 2017
β-1,3-Galactosyl-<i>O</i>-Glycosyl-Glycoprotein β-1,6-<i>N</i>-Acetylglucosaminyltransferase 3 Increases MCAM Stability, Which Enhances S100A8/A9-Mediated Cancer MotilityI Wayan Sumardika, Chen Youyi, Eisaku Kondo, et al.
JAMA Oncology|October 15, 2020
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical TrialHidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami, et al.
Plos One|February 4, 2017
Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancerTatsuaki Takeda, Hiromasa Yamamoto, Hirotaka Kanzaki, et al.
Journal of Molecular Medicine (Berlin, Germany)|November 10, 2020
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosisKota Araki, Rie Kinoshita, Nahoko Tomonobu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 3, 2019
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation BurdenGo Makimoto, Kadoaki Ohashi, Shuta Tomida, et al.
Journal of Gastroenterology|November 14, 2023
Marked intestinal trans-differentiation by autoimmune gastritis along with ectopic pancreatic and pulmonary trans-differentiationChihiro Takeuchi, Junichi Sato, Nobutake Yamamichi, et al.
Pageof 17